Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Share-based Compensation (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Share-based Compensation for 16 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 27.37% year-over-year to $19.4 million, compared with a TTM value of $67.5 million through Dec 2025, down 2.81%, and an annual FY2025 reading of $63.4 million, down 14.33% over the prior year.
  • Share-based Compensation was $19.4 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $19.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $34.6 million in Q3 2021 and bottomed at $13.0 million in Q2 2025.
  • Average Share-based Compensation over 5 years is $21.2 million, with a median of $19.4 million recorded in 2022.
  • The sharpest move saw Share-based Compensation surged 200.88% in 2021, then plummeted 40.26% in 2023.
  • Year by year, Share-based Compensation stood at $24.5 million in 2021, then fell by 20.87% to $19.4 million in 2022, then rose by 1.57% to $19.7 million in 2023, then fell by 22.77% to $15.2 million in 2024, then rose by 27.37% to $19.4 million in 2025.
  • Business Quant data shows Share-based Compensation for ARWR at $19.4 million in Q4 2025, $19.1 million in Q3 2025, and $13.0 million in Q2 2025.